用核糖体工程技术开拓海洋微生物药用资源的研究

利用核糖体工程技术对海洋中无活性的放线菌B3054进行诱导，获得了突变菌株B3054／M，其形态、菌丝体颜色都与母体菌株有显著的差异，发酵液经HPLC分析发现，代谢产物有明显的变化，特别是突变株产生了能抑制小鼠乳腺癌tsFT210细胞周期活性的活性代谢产物。这是首次利用核糖体工程技术诱变得到的具有细胞周期抑制活性的海洋放线菌菌株，这一研究结果表明，利用该技术对自然界的无活性微生物进行诱导来拓展微生物药用资源是可行的。

Studies on exploiting marine microbial resources for medicinal usage by using ribosome-engineering technology

In order to obtain active mutant strains, the ribosome-engineering technology was applied to inducing the non-active marine actinomycete strain B3054. An active mutant strain B3054/M was obtained, which showed obvious difference in the morphology and color from its parent strain B3054. The HPLC analyses of the fermentation products showed that the secondary metabolites of the mutant strain B3054/M were much different from that of the parent strain B3054. Especially, the new metabolites of the B3054/M showed cell cycle inhibitory activity on mammalian cancer tsFT210 cells. This experiment first presented the method to obtain the active marine strains with the cell cycle inhibitory activity by using the ribosome-engineering technology. It indicated that it is feasible to exploit new microbial resources for medicinal usage by the ribosome-engineering technology of inducing non-active actinomycetes in nature.